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The high cost of anti-TNFa drugs for rheumatoid arthritis: Can a low-price
product be developed in the future?Previously published epidemiology surveys have demon-
strated that the prevalence of rheumatoid arthritis (RA) is
about 0.4% of the population of Taiwan.1 In order to better
understand disease activity, we found that 26% of patients
were severe RA have a disease activity score (DAS) ＞ 5.1,
53% of patients with moderate RA have a DAS score of
3.2e5.1, and 21% with mild RA have a DAS score <3.2.
Rheumatoid arthritis is an autoimmune disease. Without
adequate treatment, a large proportion of patients develop joint
damage and deformities.2 Since 1980, methotrexate and
other nonbiological disease-modifying antirheumatic drugs
(DMARDs) (e.g., sulfasalazine, plaquenil, etc.) have been
used to treat RA, with 70e80% of patients experiencing either
symptomatic relief or a decrease in their radiologic progres-
sion. However, 20e30% of severe RA patients do not
demonstrate a good clinical response and require other
advanced therapies. By the year 2000, biologic DMARDs,
especially anti-tumor necrosis factor a (anti-TNFa) antago-
nists, had entered into the market, where they were appeared
as the miracle drugs needed to treat those RA patients who had
either a low or poor response to conventional DMARDs.3e5
Accumulating evidence shows that TNFa plays a pivotal
role in inflammatory arthritis.2 Many cells in the inflammatory
synovium, when activated, can release different cytokines.
Among them, TNFa is a potent proinflammatory cytokine that
exerts pleiotropic effects on various cell types. The biologic
functions of TNFa include: (1) activating macrophages;
(2) increasing MHC expression; (3) increasing intercellular
adhesion molecule (ICAM) and vascular cell adhesion mole-
cule (VCAM) expression; (4) decreasing the invasion of
bacteria or tuberculosis (TB)-causing bacteria; (5) enhancing
osteoclast maturation and activation; and (6) stimulating
synovial fibroblast matrix metalloproteinase (MMP) produc-
tion. The abnormal release of TNFa and MMP in RA can
cause bone and joint erosion and destruction.
Over the past 10 years, TNFa inhibitors, including eta-
nercept, have been shown to be very effective for treating
severe RA, ankylosing spondylitis (AS), and psoriatic arthritis
(PSA).3e8 Currently, five anti-TNFa blockers have been
approved and are used to manage inflammatory arthritis.
Infliximab (remicade) is the earliest-approved anti-TNFa
therapy for RA. It is administered intravenously at a dosage1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.12.012of 3e5 mg/body weight/q6weq8w. Another TNFa blocker,
etanercept (enbrel), possesses chemical structure entirely
different from that of infliximab. Etanercept can remove TNFa
because its high-affinity p75 TNFa receptor can bind to
soluble TNFa. However, infliximab can remove both soluble
and membrane-bound TNFa because the monoclonal antibody
of infliximab binds to TNFa. Different from infliximab, eta-
nercept is administered by a subcutaneous route and because
of its short half-life it should be injected every 3e4 days.
Later, in order to reduce the frequency of injection, adalimu-
mab (humira) should be administered every 14 days, and the
recently developed golimumab (simponi) can be used to
extend the period between injections to 1 month. Another
unique TNFa inhibitor, certolizumab (cimzia), is also
administered as a once-monthly injection, but its monoclonal
antibody only preserves the Fab portion of immunoglobulin
and removes the Fc portion. Among these four monoclonal
antibodies (infliximab, adalimumab, certolizumab, and goli-
mumab), only infliximab is prepared in its chimeric form
(mouse and human), while the other three are humanized.
Due to the different chemical structures and preparations,
the efficacy and side effects of these drugs are also differ-
ent.9e11 Through many randomized clinical trials that have
been conducted in the US and Europe over the last 5e10
years, the cumulative evidence demonstrates that all anti-
TNFa blockers have equal or similar efficacies for treating RA
and AS. It is obvious that anti-TNFa therapies present many
advantages for treating the clinical, pathological, and radio-
logical aspects of these diseases. In comparison with the
traditional DMARDs (e.g., methotrexate) for the treatment of
RA, TNFa blockers are superior in terms of providing pain
relief, joint function and quality of life improvements,
reducing erythrocyte sedimentation rate (ESR), c-reactive
protein (CRP), and decreased inflammation on magnetic
resonance imaging (MRI). Moreover, the rapid onset (usually
2 weeks after injection) and persistence of drug survival are
two major advantages. In spite of the high cost, anti-TNFa
drugs can easily help physicians and patients to reach the
treatment-to-target (T2 T) goals, including freedom from
clinical symptoms, the prevention of joint damage and
deformities, and long-term clinical and radiological
remission.8hinese Medical Association. All rights reserved.
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that intensive treatment, including anti-TNFa therapies, result
in a significant reduction in DAS when compared with other
routine or regular treatments.3 In 2004 and 2005, Klarslkog
and van der Heijide reported etanercept plus methotrexate
could result in clinical remission (DAS<1.6) in 36% of RA
patients, but only 16% and 13% of patients reached this goal
with etanercept alone or MTX alone, respectively.4,12 In terms
of radiologic progression, a similar trend has also been shown,
namely that the combination group fared much better than the
groups that were treated with a single drug.4,8 The Trial of
Etanercept and Methotrexate with Radiographic Patient
Outcomes (TEMPO) extension study reconfirmed that after 4
years, 47% of RA patients could achieve DAS remission (<
1.6) if treated with a combination of drugs. A more recent
study on early RA (disease duration <2 years), the Combi-
nation of Methotrexate and Etanercept in Early Rheumatoid
Arthritis (COMET) trial, demonstrated that etanercept in
combination with MTX is the optimal therapy for treating
early RA. Targeting both clinical and radiologic remission is
key to achieving an optimal outcome.8
In Taiwan, so far, only two anti-TNFa drugs are available:
etanercept and adalimumab. For adalimumab, the famous
global study was the combination therapy with Adalimumab
Plus Methotrexate Versus Methotrexate alone or Adalimumab
alone in Patients with Early, Aggressive Rheumatoid Arthritis
(PREMIER) trial. Again, the combination group (adalimumab
plus MTX) showed superior clinical results compared with
single-drug groups.5 There was no significant difference, in
terms of efficacy for treating RA, between etanercept and
adalimumab.
In order to determine the clinical effects of TNFa blockers
in a Chinese population, we have used etanercept to treat
either RA and AS over the past several years.13,14 For RA,
after 6 months of etanercept treatment, all clinical parameters,
including the number of swollen joints, disease activity score
(DAS) 28, and ESR, CRP, and anti-CCP levels, show rapid
improvements. On the other hand, the efficacy of short-term
(12 weeks) etanercept treatment for AS is much better in
Chinese patients than Caucasian patients. As far as the long-
term efficacy and safety of etanercept in Chinese pop-
ulations, it remains unknown and needs further study.
The major adverse effects of anti-TNFa therapy, particu-
larly in Chinese populations, are the reactivation of hepatitis B
or C and TB infections. In Taiwan, the prevalence of hepatitis
B surface antigen (HBSAg) carriers is approximately 15%,
and a few cases of fulminant hepatitis have been reported in
carriers who were treated with TNF blockers.11 In order to
reduce this incidence, screening patients for HBSAg and
hepatitis B virus DNA (HBVDNA) is becoming a routine
procedure, and patients should be treated if they are positive
before being administered an anti-TNFa drug. TB is still an
endemic disease in most countries in Asia, including Taiwan.
Based on data from the European registry, TNFa blockers,
especially monoclonal antibodies such as infliximab and
adalimumab, result in a higher incidence of TB compared with
etanercept.10 However, TB infection rates can be reduced ifpatients receive prophylactic treatment with isoniazid (INH) if
they show a positive purified protein derivative (PPD) skin test
or Quanteferon blood test.
Although in Taiwan government reimbursement for both
etanercept and adalimumab has been approved for the
management of severe RA, AS, and PSA, the high cost
(US$1200/month per each patient) of anti-TNFa drugs is
really a huge burden to the government and patients. In China,
a generic version of etanercept (Yisaipu) has been used to treat
RA for many years. The price is much cheaper than that of
etanercept (US$64.50/injection for Yisapu versus US$375/
injection for etanercept). However, the biological effects and
safety of this product should be carefully evaluated before
applying it clinically.
In conclusion, TNFa blockers are highly effective for
treating the clinical symptoms, as well as pathologic inflam-
mation, in early and long-standing RA patients. Earlier treat-
ment results in a better prognosis. In order to use TNFa
blockers more conveniently, relatively looser clinical guide-
lines and lower drug prices, which can be obtained by devel-
oping similar domestic products such as Tunex (see the current
issue of JCMA15), should be encouraged.
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